Regeneron and Telix form $2.1 billion radiopharmaceutical partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Regeneron and Telix Announce Strategic Radiopharma Collaboration
April 13, 2026 6:30 AM EDTRegeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing modelÂ
Collaboration combines Regenerons leading antibody discovery/development platforms and oncology experience with Telixs expertise in radiopharmaceutical development and manufacturing
Telix to receive $40 million USD upfront for four initial programs with optionality to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion USD in development and commercial milestone payments plus low double-digit royalties
TARRYTOWN, N.Y. and INDIANAPOLIS and MELBOURNE, Australia, April 13, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Telix... More
